alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 27,326–27,350 of 27,546 studies marked Peer-reviewed (page 1094 of 1102) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Neuropalliative Care in Dementia

✓ Peer-reviewed alzhub usefulness score 28 out of 100. CONTINUUM Lifelong Learning in Neurology 2025-12-01

Patients and their caregivers and families confronting dementia often face heavy burdens from difficult-to-control symptoms, uncertainty about the future, and a high risk of care partner burnout. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Unmet Activities of Daily Living (ADL) Care Needs and Associated Risk Factors Among Older Adults with Dementia at the End of Life

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Journal of Gerontological Social Work 2025-03-05

This paper examined the prevalence of and risk factors associated with unmet needs for activities of daily living (ADL) for older adults dying with dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

What are the best practices for providing end-of-life care to patients with coexisting COPD, dementia, and cancer?

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-03-04

Providing end-of-life care for patients with COPD, dementia, and cancer involves a focus on symptom management, integration of palliative care, and respecting patient preferences, while engaging families in the care process. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Needs of key stakeholders to make advance care plans and advance directives for people with dementia: a scoping review

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Repository for Publications and Research Data (ETH Zurich) 2025-11-19

Dementia-specific ACP/AD require a relational, flexible and ethically grounded approach that evolves with the individual’s condition. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effect of a Financial Incentive Scheme for Medication Review on Polypharmacy in Elderly Inpatients With Dementia: A Retrospective Before-and-After Study

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Journal of patient safety 2024-10-18

Polypharmacy is an important healthcare issue, especially in elderly patients with dementia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Short-Term Impacts of COVID-19 Public Health Regulation on Consumer Food Purchases: A Case Study From a Grocery Store in Montana

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Frontiers in Sustainable Food Systems 2022-02-01

The mitigation measures (e.g., lockdown policies) in response to the COVID-19 pandemic impacted food systems in unprecedented ways, in both scope and immediacy. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Localization of manganese superoxide dismutase in the cerebral cortex and hippocampus of Alzheimer-type senile dementia

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Osaka city medical journal 1997-06-01

Manganese-superoxide dismutase (Mn-SOD) was localized in the cerebral cortex and hippocampus of patients with Alzheimer-type senile dementia (ATD) by immunocytochemistry and the relationship of Mn-SOD with two major pathological features of ATD, i.e., senile plaques and neurofibrillar tangles (NFTs), was examined. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral extracellular preamyloid deposits in Alzheimer's disease, Down syndrome and nondemented elderly individuals

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Progress in clinical and biological research 1989-01-01

Using anti-SP28 (a polyclonal antibody to a 28 residue synthetic peptide homologous to the NH2-terminal region of Alzheimer amyloid beta-protein) to investigate the cerebral cortex of 8 Alzheimer and 6 Down patients and 13 nondemented individuals, we found that, besides senile plaques and congophilic vessels, extracellular deposits unrelated to degenerating neurites, tangle-bearing neurons or congophilic vessels were labelled. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Frequency and distribution of TUNEL-positive neurons in brains of dementia with Lewy bodies: comparison with those in brains of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Neuropathology : official journal of the Japanese Society of Neuropathology 2001-12-01

The present study investigated the frequency and distribution of TUNEL-positive neurons in brains of dementia with Lewy bodies (DLB) in comparison with those in brains of Alzheimer's disease (AD), Down syndrome (DS) and non-demented elderly persons. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The mortality of adults with Down syndrome as a function of age

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Mechanisms of ageing and development 1986-11-01

This study sought to test the hypothesis that adults with Down Syndrome may age faster than the general population by comparing the rate of increase in their mortality with age with that of the general population by the method originally described by Gompertz. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

[Parapsychotic disorders in mentally handicapped (particularly in Down's syndrome)]

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Annales medico-psychologiques 1995-12-01

Para psychotic troubles in Mentally Handicapped Persons (particularly in Down syndrome)-Clinical examples of M.H.P. which had no trouble until their 25-40 (years) except their intellectual defect and then, slide in psychiatric or para psychiatric behaviour. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

[Biomarkers in Alzheimer's disease]

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Revista de neurologia 2014-04-01

The new diagnostic criteria for Alzheimer's disease (AD) include brain imaging and cerebrospinal fluid (CSF) biomarkers, with the aim of increasing the certainty of whether a patient has an ongoing AD neuropathologic process or not. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Neurobiological studies of dementia--biological markers and neuroprotective strategies for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Acta neurologica Taiwanica 2006-03-01

Tau protein and amyloid s (Abeta), two major components of neuropathology in Alzheimer disease (AD), have been applied for establishment of more useful biomarkers and therapeutic approaches. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Etiology, risk factors, treatments and current status of Alzheimer's disease in Mexico

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Gaceta medica de Mexico 2022-01-01

Alzheimer's disease is a neurodegenerative disorder whose etiology continues to be discussed, to the point that there are different hypotheses that seek to clarify it, in addition to the fact that, given its multifactorial nature, there are different risk factors associated with its development. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

[Aducanumab and Alzheimer's disease: a critical reflection.]

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Recenti progressi in medicina 2021-07-01

On June 7, 2021, the US Food and Drug Administration (FDA) approved aducanumab, a monoclonal amyloid targeting β-amyloid, for the treatment for Alzheimer's disease (AD). 4 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed